Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17254094 | ANTIBODY CAPABLE OF INDUCING IMMUNE TOLERANCE PRODUCED USING CELL MIXTURE HAVING COMPLEXED STATE, AND INDUCED LYMPHOCYTE OR CELL THERAPEUTIC AGENT AND CELL THERAPY METHOD EACH USING INDUCED LYMPHOCYTE | December 2020 | April 2025 | Allow | 52 | 2 | 1 | No | No |
| 17127496 | ANIMAL MODEL FOR HEPATOCELLULAR CARCINOMA AND USES THEREOF | December 2020 | March 2025 | Allow | 51 | 1 | 1 | No | No |
| 17254110 | METHOD FOR ELICITING INFECTIOUS IMMUNOLOGICAL TOLERANCE | December 2020 | November 2024 | Allow | 47 | 2 | 1 | No | No |
| 17251666 | MITOCHONDRIAL AUGMENTATION THERAPY OF RENAL DISEASES | December 2020 | May 2025 | Allow | 53 | 3 | 0 | No | No |
| 17111332 | Bacteria-Based Protein Delivery | December 2020 | May 2024 | Allow | 42 | 2 | 0 | No | No |
| 17083211 | TREATMENT OF CANCER USING A CD33 CHIMERIC ANTIGEN RECEPTOR | October 2020 | February 2025 | Allow | 52 | 1 | 0 | No | No |
| 17048248 | T-CELL EXHAUSTION, METHODS & COMPOSITIONS RELATING THERETO | October 2020 | September 2024 | Abandon | 47 | 0 | 1 | No | No |
| 17045562 | Humanized Mouse Model | October 2020 | June 2025 | Abandon | 56 | 2 | 1 | No | No |
| 17042022 | USE OF HISTONE MODIFIERS TO REPROGRAM EFFECTOR T CELLS | September 2020 | August 2024 | Allow | 47 | 1 | 1 | No | No |
| 16982640 | GENE THERAPEUTICS FOR TREATING BONE DISORDERS | September 2020 | September 2024 | Allow | 56 | 2 | 0 | No | No |
| 16982881 | NOVEL METHOD FOR OBTAINING T CELLS FROM PLURIPOTENT STEM CELLS, AND USES THEREOF | September 2020 | May 2024 | Allow | 44 | 1 | 1 | No | No |
| 16982984 | CANCER THERAPY | September 2020 | March 2024 | Allow | 42 | 1 | 1 | Yes | No |
| 16982531 | CLEAN SPACE MAINTENANCE STRUCTURE, AND CELL PRODUCTION OR CULTURING METHOD | September 2020 | November 2024 | Abandon | 50 | 2 | 1 | No | No |
| 16980782 | MACROPHAGE-BASED THERAPY | September 2020 | February 2025 | Allow | 53 | 3 | 0 | Yes | No |
| 16980200 | PROCESS FOR PRODUCING CARDIAC ORGANOIDS | September 2020 | September 2024 | Abandon | 48 | 2 | 1 | No | No |
| 16978735 | COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED MACULAR DEGENERATION | September 2020 | April 2025 | Allow | 55 | 3 | 1 | No | No |
| 16977517 | IDENTIFYING AND CHARACTERIZING GENOMIC SAFE HARBORS (GSH) IN HUMANS AND MURINE GENOMES, AND VIRAL AND NON-VIRAL VECTOR COMPOSITIONS FOR TARGETED INTEGRATION AT AN IDENTIFIED GSH LOCI | September 2020 | November 2024 | Abandon | 50 | 1 | 1 | No | No |
| 16943400 | Methods for Enhancing Efficacy of Therapeutic Immune Cells | July 2020 | May 2025 | Allow | 58 | 2 | 1 | Yes | No |
| 16965955 | ICAM-1 MARKER AND APPLICATION THEREOF | July 2020 | June 2025 | Abandon | 58 | 4 | 1 | No | No |
| 16938132 | ANTIBODY GENE EDITING IN B LYMPHOCYTES | July 2020 | July 2024 | Abandon | 48 | 2 | 1 | No | No |
| 16960504 | COMPOSITIONS AND METHODS OF EXPANSION OF T CELL POPULATIONS | July 2020 | February 2024 | Allow | 44 | 2 | 1 | No | No |
| 16958118 | METHOD FOR PREPARING FUNCTIONAL HEPATIC PROGENITOR CELLS OR HEPATIC CELLS, OR FUNCTIONAL SMALL INTESTINAL EPITHELIAL PROGENITOR CELLS OR SMALL INTESTINAL EPITHELIAL CELLS | June 2020 | July 2024 | Allow | 49 | 3 | 1 | Yes | No |
| 16956894 | CONSTRUCTS COMPRISING NEURONAL VIABILITY FACTORS AND USES THEREOF | June 2020 | May 2024 | Allow | 47 | 1 | 0 | No | No |
| 16900731 | PLURIPOTENT STEM CELL-DIRECTED MODEL OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE FOR DISEASE MECHANISM AND DRUG DISCOVERY | June 2020 | February 2025 | Abandon | 56 | 2 | 2 | No | No |
| 16769821 | NON-HUMAN ANIMALS HAVING AN ENGINEERED IMMUNOGLOBULIN LAMBDA LIGHT CHAIN AND USES THEREOF | June 2020 | December 2024 | Abandon | 55 | 4 | 1 | No | No |
| 16658197 | Culture System and Media for Skin Explants Providing Enhanced Viability and Enabling Molecular Studies | October 2019 | November 2024 | Allow | 60 | 5 | 1 | No | No |
| 16335884 | METHOD FOR PREPARING A SUPPLEMENT FROM MESENCHYMAL CELL CULTURES OF WHARTON'S JELLY AND USES OF SAME | May 2019 | June 2025 | Abandon | 60 | 5 | 1 | No | No |
| 16302865 | Gene Therapy Methods for Age-Related Diseases and Conditions | November 2018 | August 2024 | Allow | 60 | 7 | 0 | Yes | No |
No appeal data available for this record. This may indicate that no appeals have been filed or decided for applications in this dataset.
Examiner AMICK, THOMAS RUSSE works in Art Unit 1638 and has examined 28 patent applications in our dataset. With an allowance rate of 64.3%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 52 months.
Examiner AMICK, THOMAS RUSSE's allowance rate of 64.3% places them in the 26% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by AMICK, THOMAS RUSSE receive 2.36 office actions before reaching final disposition. This places the examiner in the 63% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by AMICK, THOMAS RUSSE is 52 months. This places the examiner in the 5% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +43.5% benefit to allowance rate for applications examined by AMICK, THOMAS RUSSE. This interview benefit is in the 89% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 21.9% of applications are subsequently allowed. This success rate is in the 29% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 62.5% of cases where such amendments are filed. This entry rate is in the 88% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants file petitions regarding this examiner's actions, 100.0% are granted (fully or in part). This grant rate is in the 90% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 33.3% of allowed cases (in the 97% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.